S. Aureus Screening and Decolonization

• Status: Completed
• Trial end date: 2016-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Staphylococcus aureus (SA) healthcare-associated infections (HAI) cause significant morbidity and mortality. SA causes 15% of all HAI and 30% of surgical site infections (SSIs). Each year over 40 million Americans undergo operations, 1-10% of whom will acquire SSIs. Such infections double the length of hospitalization and risk of dying, and increase U.S. health care costs by $5-10 billion/year. We need effective interventions to prevent SSIs caused by either methicillin-susceptible (MSSA) or methicillin-resistant (MRSA) strains. Nasal carriers of SA (25-30% of adults) have a 2-14 times greater risk than non-carriers of acquiring an SA SSI. A potential prevention approach is routine pre-operative screening of patients, followed by decolonization of identified SA carriers.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Minnesota; University of Minnesota - Clinical and Translational Science Institute
• Collaborator: Agency for Healthcare Research and Quality (AHRQ)
• Treatments: Anti-Infective Agents, Local; Chlorhexidine; Chlorhexidine gluconate

Criteria

Inclusion Criteria:

• All patient who are 18 years and older, able to give informed consent and willing to complete the study decolonization protocol.

• Surgery must be scheduled 2 weeks in the future to allow completion of the study protocol prior to the scheduled operation.

• Patients will be admitted from home the day of the surgery or have the surgery done on an outpatient basis.

Exclusion Criteria:

• Currently on antibiotic therapy, allergy to mupirocin or CHG.